AbbVie and BMS to investigate combination therapy in solid tumour trials
AbbVie and Bristol-Myers Squibb (BMS) have entered a clinical trial collaboration to assess ABBV-399 in combination with Opdivo (nivolumab) to treat patients with non-small-cell lung cancer (NSCLC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals